Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB NSCLC
{{output}}
Objective: This study aims to predict the pathological response of patients with non-small cell lung cancer (NSCLC) in prospective trials of neoadjuvant camrelizumab combined with chemotherapy by integrating the clinical characte... ...
